Composition
Inj: 5 mg/10 mg: Idarubicin 5 mg/10 mg; powder in vial.
Indications & Dosage
Acute non-lymphocytic leukaemias monotherapy: BY IV INDUCTION: Adult: 12 mg/m2/day for 3 days; consolidation: 10-12 mg/m2/day for 2 days. Children: 10-12 mg/m2 every day for 3 day every 3 week. Acute non-lymphocytic leukaemia in combination therapy: Adult: 10-12 mg/m2 daily for 3 days. Advanced breast cancer after failure of first-linechemotherapy (not including anthracyclines); monotherapy: Adult: 15 mg/m2 daily for3 consecutive days, repeat treatment every 3-4 weeks; max. 400 mg/m2 per course. Acute leukaemias, Advanced breast cancer after failure of first-line chemotherapy (not including anthracyclines): (Consult product literature).
Administration
Administer as slow push IV over 3-5 min, preferably into the side of a freely-running saline or dextrose infusion or as intermittent infusion over 10-15 min into a free-flowing IV solution of NS or D5W; also occasionally administered as a bladder lavage. Do not administer IM or SC. Flush well with a heparin-free solution before and after idarubicin administration.
Compatibility
Stable in D5NS, D5W, LR, NS, SWFI; incompatible with bacteriostatic water. Prolonged contact with any solution of an alkaline pH will result in degradation of the drug.
Stability
Store under refrigeration at 2C-8C (36F-46E), and protect from light. Retain in carton until the time of use. Preservative-free, use solution within 24 hours of opening the vial.
Contraindications
Previous treatment with maximum cumulative dose of idarubicin or other anthracycline, recent myocardial infarction, severe arrhythmias, severe myocardial insufficiency
Precautions
Hepatic impairment & renal impairment (reduced dose)
Interactions
Live vaccines.
Pregnancy
Positive evidence of risk: Avoid
Lactation
Contraindicated. Discontinue breast-feeding
Side Effects
Abdominal pain, cardiacdisorders, diarrhoea, haemorrhage, rash, red pigmentation of the urine, nail & skin hyperpigmentation, alopecia, bone-marrow suppression, hyperuricaemia, nausea, oral mucositis, thromboembolism, tumourlysis syndrome, vomiting, extravasation